Let's go back again to charts of VIAB.
Nvidia's second-quarter profits were well below its year-ago earnings but were nicely ahead of analyst expectations.
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Sellers of the beverage company's shares have been acting more aggressively than buyers in recent weeks.
A drop in shares doesn't necessarily mean it's time to turn the channel on Viacom, as details of expected merger with CBS will prove 'paramount.'
Armed with Showtime, lots of cartoons and other mainstream shows, the CBS/Viacom merger appears to fit in between Disney Plus' family-friendly shows and Netflix's darker offerings -- but expect some drama for investors.
Only at a discount, so if there is disappointment there is some wiggle room for maneuver.
The technical signs do not instill a ton of confidence, though a bit of strength could change the outlook.
Viacom shareholders may finally be rewarded this week for their patience.
Uber's crash on earnings does not mean the stock is totaled according to analysts covering the stock.
Disney's dive after earnings could open up a buying opportunity to investors that missed the recent run.
The food giant is one of the few stocks holding its ground on Monday morning; here's why.
Following growing scandal, CannTrust Holdings is luring bargain shoppers as the stock moves higher after the company announced it's considering selling itself.
Apple has investors and analysts looking forward to its the 5G future.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
But this off-patent tie-up comes with some questions -- such as why are so many Mylan executives hanging on?
What new management means for Mylan shareholders moving forward.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Also, defense industry names can breathe easier with word of debt ceiling and federal spending deal.
The issue is whether it will inspire longer-term customer relationships.
Disappointment in the cybersecurity name could set it up as another takeover candidate.
If it wasn't clear before, Broadcom has shifted its focus away from the hardware side of the business in terms of acquisitions.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
This stock is a buy, if the fine points of the Broadcom offer support more upside.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
With no other bidder expected to emerge, this is a high risk arbitrage play.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.